The role of Pediococcus species in causing infections is a matter of debate. However, it has been isolated in sterile sites such as blood in immunosuppressed patients. Bacteremia with Pediococcus pentosaceus has only been described twice previously. We present the first case of P pentosaceus bacteremia successfully treated with daptomycin. We believe that this case report demonstrates the first reported case of P pentosaceus bacteremia treated with daptomycin. Pediococcus species has emerged as an opportunistic pathogen in immunocompromised patients. Its intrinsic resistance to vancomycin may pose a therapeutic challenge. Despite in vitro susceptibility to daptomycin, limited clinical data are available on the use of this agent to treat infections caused by Pediococcus. What makes this case even more unique is the rarity of P pentosaceus bacteremia. P acidilactici is the predominant species isolated in human infections. To date, only 2 other cases of P pentosaceus have been reported in the literature. The rarity with which this organism causes infections and the novel treatment approach make this case an important contribution to infectious diseases literature.
From the Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.
Correspondence to: Steven Ludlow, PharmD, Department of Pharmacy, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612. E-mail: email@example.com.
The authors have no funding or conflicts of interest to disclose.
This work is original and has not been published elsewhere.